(888) 552-6760 SCHEDULE AN APPOINTMENT

Jyoti Malhotra,

M.D., M.P.H.

Medical Oncologist

Biography photo
Location
City of Hope Orange County Lennar Foundation Cancer Center
1000 Five Point
Irvine, CA 92618
Education
Medical school:
Board Certifications
  • Medical Oncology/Expiration: 12/2025
  • Hematology/Expiration: 12/2026
Degrees
  • 2006, M.P.H., Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
  • 2005, M.B.B.S (M.D. equivalent), University of Delhi, India
Fellowship
  • 2012-2015, Hematology and Oncology, Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital, New York, NY
Residency
  • 2006-2009, Internal Medicine Residency, Georgetown University Hospital/ Washington Hospital Center, Washington DC
Professional Experience
  • 2022-present, Associate Professor, Department of Medical Oncology & Therapeutics Research; Director, Thoracic Medical Oncology, City of Hope Orange County, CA
  • 2021 – 2022, Associate Professor, Robert Wood Johnson Medical School, New Brunswick, NJ
  • 2015 – 2022, Attending, Rutgers Cancer Institute of New Jersey
  • 2015 – 2021, Assistant Professor, Robert Wood Johnson Medical School, New Brunswick, NJ
  • 2015 – 2016, Adjunct Assistant Professor, Icahn School of Medicine at Mount Sinai, New York, NY
  • 2010 – 2012, Instructor, Memorial Sloan Kettering Cancer Center, New York NY
Academic Appointments
  • Associate Professor, Department of Medical Oncology & Therapeutics Research
  • Director, Thoracic Medical Oncology, City of Hope Orange County
About Me

Jyoti Malhotra, M.D., M.P.H., is a medical oncologist at City of Hope® Orange County Lennar Foundation Cancer Center, where she also serves as director of thoracic medical oncology. Dr. Malhotra believes in delivering deeply personalized care that takes into account each patient’s unique values, goals and challenges, as well as the specifics of their cancer diagnosis. She specializes in treating lung and thoracic cancers. Dr. Malhotra also works closely with patients who have treatment-resistant solid tumors through her role in City of Hope’s Phase I/Early Therapeutics program.

As director of thoracic medical oncology at City of Hope Orange County, Dr. Malhotra is passionate about expanding access to innovative therapies by offering patients access to early-phase clinical trials. Her research focus is on experimental therapeutics, and in this area, Dr. Malhotra has led numerous Phase I studies involving new drug combinations and therapeutics, including several first-in-human clinical trials. Her goal is to integrate leading-edge developments in precision medicine with immunotherapy to enhance the body’s natural ability to fight cancer. 

Dr. Malhotra has an extensive track record in clinical research, having served as principal investigator on over 50 trials and led seven investigator-initiated studies. Her scholarly work includes more than 100 publications, book chapters and scientific abstracts and she is an active member of advisory groups including the National Comprehensive Cancer Network’s guideline panel for small cell lung cancer and the Southwest Oncology Group’s thoracic committee. 

After earning her medical degree at Maulana Azad Medical College at the University of Delhi in India, Dr. Malhotra completed a master of public health degree at Johns Hopkins University’s Bloomberg School of Public Health in Baltimore. She then pursued a residency in internal medicine at Georgetown University/Washington Hospital Center in Washington, D.C., and a fellowship in oncology and hematology at Mount Sinai Medical Center in New York City. Her prior academic roles include positions at Mount Sinai, the Rutgers Cancer Institute of New Jersey, where she directed the Phase I/Investigational Therapeutics program, and Memorial Sloan Kettering Cancer Center.

Patient ratings
Star ratings and comments are only available for medical, radiation and gynecologic oncologists. Gynecologic surgical offerings are not included at this time due to a different survey tool required to evaluate these services. CTCA uses a validated Press Ganey® survey, which captures patient experience feedback for the primary oncology services of chemotherapy and radiation therapy at our comprehensive care and research centers. Following industry best practice, star ratings and comments are only published for physicians with a minimum of 30 completed patient surveys.